

LSP Life Sciences Fund

Monthly Report December 2018



NAV per Share € 214.48

Performance

| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 3 Years | 5 Years |
|-------|---------|----------|--------|---------|---------|---------|
| -8.8% | -9.8% | -18.3% | -8.8% | 26.6% | 1.2% | 16.4% |

NAV of Fund 71,476,972

Number of Shares 333,247

Valuation Date 31/12/2018

Top-5 performers

| | |
|------------------------|-------|
| 1. Merus | 12.8% |
| 2. CytomX Therapeutics | 9.4% |
| 3. FibroGen | 7.7% |
| 4. Genmab | 6.4% |
| 5. Cocrysal Pharma | 2.9% |

| | |
|------------------|--------------------------------|
| Inception date: | 27/04/2011 |
| Currency: | Euro |
| Domicile: | The Netherlands |
| Legal Structure: | Dutch NV with variable capital |
| Listing: | Euronext Amsterdam |
| Euronext code: | LSP |
| ISIN Code: | NL0009756394 |
| Bloomberg: | LSP NA |


Investment strategy

The Fund's primary investment objective is to achieve capital appreciation by investing in a diversified, yet concentrated portfolio of publicly listed life sciences companies (including biopharmaceutical-, specialist pharmaceutical-, medical device-, drug delivery-, vaccine- and diagnostic companies). The majority of the Fund's portfolio will consist of European companies listed on one of the (main) European stock exchanges, with a market capitalization of below € 2.5 billion at the time of investment.

Manager's comments

We have published an extensive yearly review of 2018 on the website, the document can be accessed via this [link](#).

Portfolio breakdown



LSP Life Sciences Fund



Portfolio breakdown

| Company | Stage | Subsector | Marketcap | % |
|---------------------------|--------|--------------|-----------|-------|
| argenx | Late | Therapeutics | Mid | 12.3% |
| Galapagos | Late | Therapeutics | Mid | 7.9% |
| Evotec | Early | Therapeutics | Mid | 7.3% |
| Amarin Corp | Market | Therapeutics | Mid | 6.9% |
| Morphosys | Late | Therapeutics | Mid | 6.8% |
| Genmab | Market | Therapeutics | Mid | 5.9% |
| ObsEva | Late | Therapeutics | Small | 5.8% |
| Foamix Pharmaceuticals | Late | Therapeutics | Small | 5.4% |
| Cocrystal Pharma | Early | Therapeutics | Micro | 4.6% |
| Aerie Pharmaceuticals | Market | Therapeutics | Mid | 4.6% |
| Zogenix | Late | Therapeutics | Mid | 4.4% |
| Stemline Therapeutics | Late | Therapeutics | Small | 4.4% |
| CytomX Therapeutics | Early | Therapeutics | Small | 4.3% |
| Verastem | Late | Therapeutics | Small | 4.2% |
| Uniqure | Late | Therapeutics | Small | 4.2% |
| Merus | Early | Therapeutics | Small | 3.4% |
| FibroGen | Late | Therapeutics | Mid | 2.7% |
| Eloxx Pharmaceuticals | Early | Therapeutics | Small | 1.9% |
| Viking Therapeutics | Early | Therapeutics | Mid | 1.8% |
| Clementia Pharmaceuticals | Late | Therapeutics | Small | 0.5% |

Important information

LSP Advisory B.V. (as Fund Manager) and the LSP Life Sciences Fund N.V. (the Fund) have a license and are registered pursuant to the Dutch Act on Financial Supervision and are supervised by the Stichting Autoriteit Financiële Markten (Dutch Authority for the Financial Markets) and De Nederlandsche Bank N.V. (the Dutch Central Bank). This presentation is solely for information purposes and is not intended as advice in any way. The Fund Manager and the Fund cannot be held liable or responsible for the content of this presentation. Potential investors are advised to contact their investment- and fiscal advisor prior to taking an investment decision. There are risks involved in the investment. The value of the investment can fluctuate. Results achieved in the past offer no guarantee for the future. A Key Investor Information Document is also available for this product with information about the product, the costs and the risks involved. Read it before you invest in the product. The prospectus and the Key Investor Information Document of the LSP Life Sciences Fund can be downloaded via www.lspvc.com/funds/public.html

In Switzerland, the Fund may only be offered or distributed to qualified investors. For this, the Fund has appointed as Swiss Representative Oligo Swiss Fund Services SA, Av. Villamont 17, 1005 Lausanne, Switzerland, Tel: +41 21 311 17 77, email: info@oligofunds.ch. The Fund's paying agent is Banque Cantonale de Genève. Any Fund Documentation may be obtained free of charge from the Swiss Representative in Lausanne.